Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

High-Intensity Interval Training, Inflammatory Biomarkers, and Circulating MicroRNAs in Human Clinical Obesity.

16. november 2026 oppdatert av: Sofia Uribe-Cerda, Universidad Nacional Andres Bello

Effects of High-Intensity Interval Training on Body Composition, Inflammatory Biomarkers, and Circulating MyomiRs in Adults With Clinical Obesity: A Randomized Controlled Trial.

This randomized controlled trial evaluates the effects of high-intensity interval training (HIIT) on body composition, inflammatory biomarkers, and circulating microRNAs in adults with clinical obesity. Circulating microRNAs are small regulatory molecules that may reflect exercise-induced adaptations and inter-tissue communication related to skeletal muscle and metabolic health. The study investigates whether exercise-induced changes in adiposity are accompanied by changes in inflammatory status and circulating microRNA profiles associated with skeletal muscle adaptations and metabolic health.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Clinical obesity is characterized by excessive adiposity accompanied by impaired metabolic health and chronic low-grade inflammation. Emerging evidence suggests that obesity is also associated with alterations in circulating molecular biomarkers that may influence skeletal muscle function and inter-tissue communication.

High-intensity interval training (HIIT) is an effective exercise strategy for improving body composition and cardiometabolic health; however, the molecular mechanisms underlying these adaptations remain incompletely understood. In particular, limited information is available regarding the response of circulating muscle-related microRNAs (myomiRs) to exercise interventions in adults with clinical obesity.

This randomized controlled trial is designed to investigate physiological and molecular adaptations to HIIT in adults with clinical obesity. The study will examine the relationship between changes in adiposity, systemic inflammation, and circulating microRNA expression following a supervised exercise intervention. Circulating microRNAs may provide insight into exercise-responsive biological pathways and represent potential biomarkers of skeletal muscle adaptation and metabolic health.

The findings may improve understanding of the molecular mechanisms associated with exercise-induced health benefits in clinical obesity and contribute to the identification of novel biomarkers relevant to obesity management and precision exercise medicine.

Studietype

Intervensjonell

Registrering (Antatt)

17

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Metropolitan Region
      • Santiago, Metropolitan Region, Chile
        • Exercise and Rehabilitation Sciences Institute, School of Physical Therapy, Faculty of Rehabilitation Sciences, Universidad Andres Bello.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

20 år til 39 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 20 to 39 years.
  • Clinical obesity defined primarily by body fat percentage (>29% in women and >20% in men), complemented by body mass index (BMI ≥30 kg/m²) and waist-to-height ratio (≥0.55).
  • Low habitual physical activity level, defined as not meeting the criteria for moderate or high physical activity according to the International Physical Activity Questionnaire-Short Form (IPAQ-SF).

Exclusion Criteria:

  • Cardiovascular disease.
  • Metabolic disease (e.g., type 2 diabetes mellitus or dyslipidemia).
  • Inflammatory or autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, or psoriasis).
  • Current smoking.
  • Chronic medication use that may affect metabolic or inflammatory outcomes.
  • Pregnancy and lactation.
  • Participation in a structured exercise program within the previous 6 months. Contraindications to high-intensity exercise.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: High-Intensity Interval Training (HIIT)

Participants assigned to this arm will complete a supervised high-intensity interval training (HIIT) program performed on a cycle ergometer three times per week during 8 weeks. Each training session will last approximately 30 minutes and include a warm-up, high-intensity intervals performed at approximately 90% of maximal power output, active recovery periods, and a cool-down. All sessions will be supervised by qualified personnel to ensure participant safety and adherence to the protocol.

Participants will complete a supervised high-intensity interval training (HIIT) program performed on a cycle ergometer three times per week during eight weeks. Each session will last approximately 30 minutes and consist of a warm-up, ten 1-minute high-intensity intervals performed at approximately 90% of maximal power output, interspersed with 1-minute active recovery periods, and a cool-down. Training intensity will be reassessed midway through the intervention to ensure appropriate progression. All sessions will be supervised by qualified personnel to promote adherence, proper exercise execution, and participant safety.

Ingen inngripen: Control

Participants assigned to this arm will maintain their habitual lifestyle without participating in a structured exercise program during the intervention period. Educational materials on healthy lifestyle habits will be provided at the end of the study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total Body Fat Mass Assessed by Bioelectrical Impedance Analysis
Tidsramme: Change from baseline to Week 8

Total body fat mass (kg) will be assessed using bioelectrical impedance analysis and compared between baseline and post-intervention measurements.

Change from baseline to Week 8

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Plasma Interleukin-1β (IL-1β) and Tumor Necrosis Factor-α (TNF-α) concentration Assessed by ELISA
Tidsramme: From baseline to Week 8

Plasma IL-1β concentration (pg/mL) and TNF-α concentration (pg/mL) measured by enzyme-linked immunosorbent assay (ELISA).

From baseline to Week 8
Circulating Myo-MicroRNAs
Tidsramme: from enrollment to the end of treatment at 8 weeks

Change in circulating expression of miR-1, miR-133, and miR-206 quantified by RT-qPCR.

from enrollment to the end of treatment at 8 weeks
Peak Oxygen Uptake (VO₂peak)
Tidsramme: From baseline to Week 8

Change in cardiorespiratory fitness assessed by peak oxygen uptake during an incremental cycling test.

From baseline to Week 8
Handgrip Strength
Tidsramme: From baseline to Week 8

Change in maximal handgrip strength assessed using a hydraulic hand dynamometer.

From baseline to Week 8
Maximal Voluntary Isometric Contraction (MVC)
Tidsramme: From baseline to Week 8

Change in maximal isometric strength of the knee extensor muscles measured by dynamometry.

From baseline to Week 8
Health-Related Quality of Life Assessed Using the 36-Item Short Form Health Survey (SF-36)
Tidsramme: From baseline to Week 8

Change in health-related quality of life assessed using the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better perceived health status and quality of life.

From baseline to Week 8

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. oktober 2027

Datoer for studieregistrering

Først innsendt

29. oktober 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere